Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kelvin Cooper
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Beta
- -4.76
- Country
- US
Financials
LABT has only 10 quarterly periods on file — the charts below show the full history available.
Net Income
$-3.77MEBITDA
$-3.73MFree Cash Flow
$-2.10MEPS (diluted)
$-2.75Shares Outstanding (diluted)
1.42M+106.4%Operating Expenses
$3.79MCash & Debt
$4.58MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-3.85M | $-2.76 |
| 2024 | $0.00 | $-4.86M | $-6.94 |
| 2023 | $0.00 | $-8.28M | $-11.84 |
Valuation
LABThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (8)
- Newsprnewswire.com·17d ago·Negative
Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption SARASOTA, Fla., Nov. 5, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc.
View source ↗ - Newsprnewswire.com·32d ago·Positive
…d its potential as a topical treatment for infected diabetic foot ulcers SARASOTA, Fla., Oct. 21, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the presentation of research highlighting the antimicrobial profile of Nu-3, the Company's lead clinical candidate, at IDW…
View source ↗ - Newsprnewswire.com·46d ago·Neutral
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds Intravesical administration of the Bisphosphocin ® Nu-8 to rodents infected with E. coli demonstrated up to 97% inhibition of E.
View source ↗ - Newsprnewswire.com·52d ago·Neutral
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences SARASOTA, Fla., Oct. 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that CEO Kelvin Cooper, Ph.D.
View source ↗ - Newsprnewswire.com·55d ago·Neutral
…pidly kill microbes while reducing the risk of antimicrobial resistance SARASOTA, Fla., Sept. 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, announced positive Minimum Inhibitory Concentration (MIC) data from recent clinical isolates for its lead clinical candidate, Nu-3.
View source ↗ - Newsprnewswire.com·59d ago·Neutral
…timicrobial platform Topline data expected in the first quarter of 2027 SARASOTA, Fla., Sept. 24, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that the first patient has been dosed in its Phase 2a clinical trial evaluating Nu-3 for the treatment of patients with mi…
View source ↗ - Newsprnewswire.com·62d ago·Positive
…ighlighting Transformational Progress and Outlook for Nu-3 Clinical and Corporate Highlights Successfully listed on the Nasdaq Capital Market under the ticker symbol LABT, marking a significant milestone in the Company's evolution Strengthened balance sheet through completion of a $7.5 million private placement to support continued clinical advancement Reported positive preclinical safety and tolerability data supporting dose selection for the upcoming Phase 2a clinical trial evaluating Nu-3 Gel…
View source ↗ - Newsprnewswire.com·65d ago·Neutral
…inical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers SARASOTA, Fla., Sept. 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that it has obtained central and all site Institutional Review Board (IRB) approvals and confirmed clinical trial site rea…
View source ↗
Earnings
Mon, Feb 15(in 3 months)
Consensus estimate $-0.34 per share
Typical surprise +25.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-0.62 vs $-1.33beat
- Thu, Aug 13$-2.75 vs $-2.66miss
Estimates and results for LABT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LABT officers and directors.
No open-market trades in the recent filings. All 26 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
26 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LABT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
